PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 7:55 AM ET

Sponsor Check › Person

SS
No photo found yet (own website and image search run after this page is viewed)

Sandesh Seth

Named as an officer, director or promoter on SEC Form D filings · NY · Dec 31, 2012 → Jun 19, 2014

4deals (issuers)
$37.5Mreported sold
1,063investors
8Form D filings
2012–2014years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:26 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Sandesh Seth is listed as a director on 8 SEC Form D filings by 4 issuers between Dec 2012 and Jun 2014: Relmada Therapeutics, Inc. (New York, NY — biotechnology — 2013–2014; $15.1M reported sold to 225 investors), RELMADA THERAPEUTICS, INC. (New York, NY — biotechnology — 2014; $10.7M reported sold to 382 investors), Actinium Pharmaceuticals, Inc. (New York, NY — pharmaceuticals — 2014; $6.64M reported sold to 348 investors) and Actinium Pharmaceuticals, Inc. (New York, NY — pharmaceuticals — 2012; $5.14M reported sold to 108 investors).

What this means A repeat sponsor — 4 separate companies raised money with this person listed as director, over about 2 years. Across those companies the filings report $37.5M sold in total.

Listed alongside Sergio Traversa (8 shared filings), David Nicholson (3 shared filings), Douglas Beck (3 shared filings), Dragan Cicic (3 shared filings), Eliseo O. Salinas (3 shared filings) and 7 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Sandesh. Each name links to their own page.

All 4 issuers belong to the sponsor group Relmada Therapeutics (5 issuers, $28.9M reported sold, 2009–2019).

What this means A sponsor group is one team that sets up a new company for each deal. Relmada Therapeutics has 5 companies on file and $28.9M reported sold in total — the group page shows the whole track record in one place.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.

What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.

We compared 8 public filings for Sandesh Seth and found 12 differences, 1 worth asking the sponsor about: Form D filed 183 days after the first sale; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Sandesh Seth has not run yet — it is joining a line of 28,969 names; searches run around the clock at the hosts' allowed rate. Searched so far: 638 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:26 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: VA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Sandesh Seth..

State securities regulators: Securities regulators searched (3,318 actions): AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE DOJ Investor Protection Unit (257 actions, 1987–2026), TX State Securities Board (586 actions, 2006–2026), WA DFI (2,039 actions, 2001–2026) — last crawled Oct 23, 2026, 9:57 PM ET. No machine-readable public listing today for CO, FL, IA, IN, MN, NE, NJ, NY, OH, UT, VA (see docs/state-regulators.md).

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:26 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

12 differences found between the filings for Sandesh Seth — 1 worth asking about (compared 8 filings on Oct 24, 2026)

Note · Feb 20, 2018 – Jan 31, 2019

Bankruptcy case: Traversa, Jr. v. Erie Avenue Storage Inc. — filed Feb 20, 2018

United States Bankruptcy Court, E.D. Pennsylvania docket "Traversa, Jr. v. Erie Avenue Storage Inc." filed Feb 20, 2018, closed Jan 31, 2019. Sergio Traversa (listed on the same filings) is listed as Plaintiff ("Traversa, Jr."). Our match estimate: 70%.

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, E.D. Pennsylvania ↗Sergio Traversa — PartnerFacts page ↗
Sources
Note · Dec 31, 2012

12% of the money raised went to insiders — Actinium Pharmaceuticals, Inc.

The Dec 31, 2012 Form D reports $5,141,450 sold and $600,000 of the proceeds used for payments to officers, directors or promoters (marked as an estimate).

What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.

Form D · Dec 31, 2012 ↗Actinium Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Dec 31, 2012

Sandesh Seth appears on 1 deal that stopped filing before reaching its target

Actinium Pharmaceuticals, Inc. (last filing Dec 31, 2012; $5,141,450 sold of $15,000,000). Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

Actinium Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Worth asking · Dec 6, 2012 – Jun 7, 2013

Form D filed 183 days after the first sale — Relmada Therapeutics, Inc.

The filing says the first sale was Dec 6, 2012. The Form D was filed Jun 7, 2013 — 183 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 168 days past that.

What this means The notice went in months after money was taken in. Late notices are common and carry no penalty by themselves, but it is fair to ask the sponsor why the paperwork lagged.

Form D · Jun 7, 2013 ↗Relmada Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Dec 6, 2012 – Jun 7, 2013

No amendment in the last 12 months on an offering that may still be open — Relmada Therapeutics, Inc. (latest filing Jun 7, 2013)

The latest filing for this offering is dated Jun 7, 2013 (first sale Dec 6, 2012). It reports $180,000 sold of $750,000 offered. No later amendment is in our index as of Oct 24, 2026.

What this means SEC rules expect a yearly amendment while an offering is still going. The raise may simply have ended — a Form D does not say when it closed. Ask the sponsor whether the offering closed, when, and at what amount.

Form D · Jun 7, 2013 ↗Relmada Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Jul 10, 2012 – Jun 6, 2013

No amendment in the last 12 months on an offering that may still be open — Relmada Therapeutics, Inc. (latest filing Jun 6, 2013)

The latest filing for this offering is dated Jun 6, 2013 (first sale Jul 10, 2012). It reports $4,955,500 sold of $8,000,000 offered. No later amendment is in our index as of Oct 24, 2026.

What this means SEC rules expect a yearly amendment while an offering is still going. The raise may simply have ended — a Form D does not say when it closed. Ask the sponsor whether the offering closed, when, and at what amount.

Form D/A · Jun 6, 2013 ↗Relmada Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Dec 19, 2012 – Dec 31, 2012

No amendment in the last 12 months on an offering that may still be open — Actinium Pharmaceuticals, Inc. (latest filing Dec 31, 2012)

The latest filing for this offering is dated Dec 31, 2012 (first sale Dec 19, 2012). It reports $5,141,450 sold of $15,000,000 offered. No later amendment is in our index as of Oct 24, 2026.

What this means SEC rules expect a yearly amendment while an offering is still going. The raise may simply have ended — a Form D does not say when it closed. Ask the sponsor whether the offering closed, when, and at what amount.

Form D · Dec 31, 2012 ↗Actinium Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Jan 7, 2014 – Jan 21, 2014

Offering amount changed between filings — Actinium Pharmaceuticals, Inc.

The Jan 7, 2014 filing says $6,000,000 offered; the Jan 21, 2014 Form D/A says $6,636,720.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Jan 7, 2014 ↗Form D/A (later) · Jan 21, 2014 ↗Actinium Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Jul 23, 2012 – Jun 6, 2013

Offering amount changed between filings — Relmada Therapeutics, Inc.

The Jul 23, 2012 filing says $6,000,000 offered; the Jun 6, 2013 Form D/A says $8,000,000.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Jul 23, 2012 ↗Form D/A (later) · Jun 6, 2013 ↗Relmada Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Jul 23, 2012 – May 22, 2014

Industry group changed between filings — Relmada Therapeutics, Inc.

"Pharmaceuticals" (Jul 23, 2012 to Jun 7, 2013); then "Biotechnology" (May 22, 2014).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Jul 23, 2012 ↗Form D · May 22, 2014 ↗Relmada Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Jul 23, 2012 – May 22, 2014

Reported revenue range changed between filings — Relmada Therapeutics, Inc.

"Decline to Disclose" (Jul 23, 2012); then "No Revenues" (May 22, 2014).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · Jul 23, 2012 ↗Form D · May 22, 2014 ↗Relmada Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Jul 23, 2012 – Jun 6, 2013

Address moved from Blue Bell, PA to New York, NY — Relmada Therapeutics, Inc.

The people listed on the Jul 23, 2012 filing give Blue Bell, PA; on the Jun 6, 2013 filing they give New York, NY. The address now on file (546 Fifth Avenue, 14th Floor, New York, NY) is a registered-agent or shared-office address used by 7 issuers.

What this means A registered agent's address is a mailbox, not where the team works. Ask where the business actually operates.

Form D · Jul 23, 2012 ↗Form D/A · Jun 6, 2013 ↗Relmada Therapeutics, Inc. — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

6 of 7 offerings report sales commissions totalling $4,670,987; 0 report finder's fees; 2 report proceeds to related persons totalling $825,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jun 19, 2014 D
RELMADA THERAPEUTICS, INC.
File 021-219502
$1,069,458$0$0
In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.
Laidlaw & Company (UK) Ltd. BrokerCheck CRD 119037 ↗EDGAR ↗
Jun 4, 2014 D
RELMADA THERAPEUTICS, INC.
File 021-218540
$0$0$0None listed on this filingEDGAR ↗
May 22, 2014 D
Relmada Therapeutics, Inc.
File 021-217828
$1,806,133$0$0
In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.
Laidlaw & Company (UK) Ltd. BrokerCheck CRD 119037 ↗EDGAR ↗
Jan 21, 2014 D/A
Actinium Pharmaceuticals, Inc.
File 021-209458
$663,672$0$0
In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.
Recipient Laidlaw & Company (UK) Ltd. BrokerCheck CRD 119037 ↗EDGAR ↗
Jun 7, 2013 D
Relmada Therapeutics, Inc.
File 021-197621
$18,000$0$0Laidlaw & Company (UK) Ltd. BrokerCheck CRD 119037 ↗EDGAR ↗
Jun 6, 2013 D/A
Relmada Therapeutics, Inc.
File 021-181601
$495,550$0$225,000
The amount set forth above covers the annual compensation for one of the persons set forth in item 3.
Laidlaw & Company (UK) Ltd. BrokerCheck CRD 119037 ↗EDGAR ↗
Dec 31, 2012 D
Actinium Pharmaceuticals, Inc.
File 021-189157
$618,174$0$600,000 (est.)Laidlaw & Company (UK) Ltd. BrokerCheck CRD 119037 ↗EDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 4

Every issuer that named Sandesh Seth on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

RT
Biotechnology · group: Relmada Therapeutics

RELMADA THERAPEUTICS, INC.

New York, NY · Jun 4, 2014 → Jun 19, 2014 · 2 filings
  • Jun 19, 2014 · D · $10,694,588 sold of $10,694,588 · 236 investors · min. $100,000 · role: Director (Lead Director) EDGAR ↗
  • Jun 4, 2014 · D · $0 sold of $0 · 382 investors · min. No minimum reported · role: Director (Lead Director) EDGAR ↗

Raised $10.7M from 382 investors (100% of the $10.7M target) as of the latest filing. Sandesh is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RT
Biotechnology · group: Relmada Therapeutics

Relmada Therapeutics, Inc.

New York, NY · Jun 6, 2013 → May 22, 2014 · 3 filings
  • May 22, 2014 · D · $15,051,110 sold of $15,051,110 · 225 investors · min. $100,000 · role: Director (Lead Director) EDGAR ↗
  • Jun 7, 2013 · D · $180,000 sold of $750,000 · 6 investors · min. $15,000 · role: Director EDGAR ↗
  • Jun 6, 2013 · D/A · $4,955,500 sold of $8,000,000 · 98 investors · min. $4,900 · role: Director EDGAR ↗

Raised $15.1M from 225 investors (100% of the $15.1M target) as of the latest filing. Sandesh is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AP
Pharmaceuticals · group: Relmada Therapeutics

Actinium Pharmaceuticals, Inc.

New York, NY · Jan 7, 2014 → Jan 21, 2014 · 2 filings
  • Jan 21, 2014 · D/A · $6,636,720 sold of $6,636,720 · 63 investors · min. $5,000 · role: Director (Chairman of the Board) EDGAR ↗
  • Jan 7, 2014 · D · $3,325,860 sold of $6,000,000 · 36 investors · min. $5,000 · role: Director (Chairman of the Board) EDGAR ↗

Raised $6.64M from 348 investors (100% of the $6.64M target) as of the latest filing. Sandesh is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AP
Pharmaceuticals · group: Relmada Therapeutics

Actinium Pharmaceuticals, Inc.

New York, NY · Dec 31, 2012
  • Dec 31, 2012 · D · $5,141,450 sold of $15,000,000 · 108 investors · min. $3,000 · role: Director EDGAR ↗

Raised $5.14M from 108 investors (34% of the $15M target) as of the latest filing. Sandesh is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

People around Sandesh 12

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET.

ST
No photo found yet (own website and image search run after this page is viewed)
Person

Sergio Traversa

Director, Executive Officer · 8 shared filings (4 issuers) · also on 2 other issuers

Sergio Traversa is on 6 issuers in total — a repeat sponsor. Their page lists every one.

DN
No photo found yet (own website and image search run after this page is viewed)
Person

David Nicholson

Director · 3 shared filings (2 issuers) · also on 4 other issuers

David Nicholson is on 6 issuers in total — a repeat sponsor. Their page lists every one.

NY
No photo found yet (own website and image search run after this page is viewed)
Person

Nabil M. Yazgi

Director · 3 shared filings (2 issuers)

Listed on the same filings as Sandesh Seth. Their page shows their other deals.

DB
No photo found yet (own website and image search run after this page is viewed)
Person

Douglas Beck

Executive Officer · 3 shared filings (2 issuers)

Listed on the same filings as Sandesh Seth. Their page shows their other deals.

SA
No photo found yet (own website and image search run after this page is viewed)
Person

Shreeram Agharkar

Director · 3 shared filings (2 issuers)

Listed on the same filings as Sandesh Seth. Their page shows their other deals.

ES
No photo found yet (own website and image search run after this page is viewed)
Person

Eliseo O. Salinas

Executive Officer · 3 shared filings (2 issuers)

Listed on the same filings as Sandesh Seth. Their page shows their other deals.

DC
No photo found yet (own website and image search run after this page is viewed)
Person

Dragan Cicic

Executive Officer · 3 shared filings (2 issuers)

Listed on the same filings as Sandesh Seth. Their page shows their other deals.

RS
No photo found yet (own website and image search run after this page is viewed)
Person

Richard I. Steinhart

Director · 2 shared filings (1 issuer)

Listed on the same filings as Sandesh Seth. Their page shows their other deals.

KD
No photo found yet (own website and image search run after this page is viewed)
Person

Kaushik J. Dave

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Sandesh Seth. Their page shows their other deals.

EG
No photo found yet (own website and image search run after this page is viewed)
Person

Enza Guagenti

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Sandesh Seth. Their page shows their other deals.

JT
No photo found yet (own website and image search run after this page is viewed)
Person

Jack V. Talley

Executive Officer, Director · 1 shared filing (1 issuer) · also on 1 other issuer

Listed on the same filings as Sandesh Seth. Their page shows their other deals.

RM
No photo found yet (own website and image search run after this page is viewed)
Person

Rosemary Mazanet

Director · 1 shared filing (1 issuer) · also on 3 other issuers

Listed on the same filings as Sandesh Seth. Their page shows their other deals.

The team behind the deals

RT
Sponsor group

Relmada Therapeutics

5 issuers · 24 filings · $28.9M reported sold · 2009–2019

One team, 5 deal companies. Sandesh Seth is listed on 4 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Sandesh Seth.

Registrations and other filings

Adviser registration (Form ADV)

None of the 4 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Sandesh Seth by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 4 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Sandesh Seth is listed on: none on file. No website or social profile named in Actinium Pharmaceuticals, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #334,361 of 374,652 in line (1,373 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (New York, NY). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗New York WebCivil Supreme ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

New York Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Sandesh Seth appears on a new Form D, or when a court case or SEC action is matched to them. See plans →